Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.

Grannell A, Martin WP, Dehestani B, Al-Najim W, Murphy JC, le Roux CW

Obesity (Silver Spring, Md.)2 Feb 2021Cited by 19 (Europe PMC)

PMID33528919DOI10.1002/oby.23098PepBankPUB-33528919

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with BMI of 35 kg/m2 or more, liraglutide 3.0 mg with lifestyle intervention gave more weight loss than lifestyle intervention alone (-12.2 kg versus -9.7 kg).
In plain wordsIn adults with severe obesity, liraglutide plus lifestyle advice led to more weight loss than lifestyle advice alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 16 weeks
Study
n = 78
Comparator
Lifestyle intervention alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 16 weeksAs given in this study (human).
Measurements
weight change
−12.2 kg
lifestyle plus liraglutide
weight change
−9.7 kg
lifestyle alone
Source sentences
Summary
Compared with lifestyle intervention alone, participants on liraglutide lost more weight (-12.2 kg vs. -9.7 kg, P = 0.048) and FFM (-2.3 kg vs. -1.5 kg, P = 0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
Report a problemFND-3352891901
02HumanNon-randomized trialEfficacy outcome
In adults with BMI of 35 kg/m2 or more, fat-free mass loss with liraglutide plus lifestyle (-2.3 kg) was not significantly different from lifestyle alone (-1.5 kg, P = 0.06).
In plain wordsIn adults with severe obesity, the loss of lean body mass with liraglutide was not clearly different from lifestyle advice alone.
Peptide
Liraglutide
Outcome
No significant changeFat-free mass loss at 16 weeks
Study
n = 78
Comparator
Lifestyle intervention alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 16 weeksAs given in this study (human).
Measurements
fat-free mass change
−2.3 kg
lifestyle plus liraglutide
fat-free mass change
−1.5 kg
lifestyle alone
Source sentences
Summary
Compared with lifestyle intervention alone, participants on liraglutide lost more weight (-12.2 kg vs. -9.7 kg, P = 0.048) and FFM (-2.3 kg vs. -1.5 kg, P = 0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
Report a problemFND-3352891902
03HumanNon-randomized trialEfficacy outcome
After controlling for weight loss, there was no difference in fat-free mass loss between liraglutide plus lifestyle and lifestyle alone.
In plain wordsIn adults with severe obesity, once weight loss was taken into account, lean body mass loss with liraglutide was not different from lifestyle advice alone.
Peptide
Liraglutide
Outcome
No significant changeFat-free mass loss per kg weight loss (adjusted for weight loss)
Study
n = 78
Comparator
Lifestyle intervention alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 16 weeksAs given in this study (human).
Source sentences
Summary
After controlling for weight loss, there was no difference in FFM loss between groups (0.14 kg/wk vs. -0.09 kg/wk, P = 0.12).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
Report a problemFND-3352891903

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneNon-randomized trialOther
In both groups combined, absolute weight loss was associated with fat-free mass loss (rho = 0.58).
In plain wordsIn adults with severe obesity, people who lost more weight also lost more lean body mass.
Peptide
Liraglutide
Outcome
Not applicableAssociation of weight loss with fat-free mass loss
Study
n = 78
Comparator
Lifestyle intervention alone
Outcome group
Body weight · Metabolic and weight
Measurements
correlation rho
0.58
weight loss vs fat-free mass loss
Source sentences
Summary
Absolute weight loss (kilograms) was associated with FFM loss (kilograms) (ρ = 0.58, P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3352891904
05HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In adults with BMI of 35 kg/m2 or more, exercise did not increase weight loss.
In plain wordsIn adults with severe obesity, exercise did not lead to more weight loss.
Peptide
Liraglutide
Outcome
No significant changeEffect of exercise on weight loss
Study
n = 78
Outcome group
Exercise and physical function · Metabolic and weight
Source sentences
Summary
Exercise did not increase weight loss, and resistance training frequency (days per week) did not attenuate FFM loss.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3352891905
06HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In adults with BMI of 35 kg/m2 or more, resistance training frequency did not attenuate fat-free mass loss.
In plain wordsIn adults with severe obesity, more days of resistance training did not reduce the loss of lean body mass.
Peptide
Liraglutide
Outcome
No significant changeEffect of resistance training frequency on fat-free mass loss
Study
n = 78
Outcome group
Exercise and physical function · Metabolic and weight
Source sentences
Summary
Exercise did not increase weight loss, and resistance training frequency (days per week) did not attenuate FFM loss.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective study examined patients with BMI ≥ 35 kg/m² receiving treatment in a tertiary care obesity clinic.
Summary · context
A total of 78 individuals were examined in two groups, the first with lifestyle intervention alone (n = 19) and the second with lifestyle intervention plus liraglutide 3.0 mg (n = 59).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3352891906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.